Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay

Brand I, Gilberg L, Bruger J, Gari M, Wieser A, Eser TM, Frese J, Ahmed MIM, Rubio-Acero R, Guggenbuehl Noller JM, Castelletti N, et al. (2021)
Frontiers in Immunology 12: 688436.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
OA 980.50 KB
Autor*in
Brand, Isabel; Gilberg, Leonard; Bruger, Jan; Gari, Merce; Wieser, Andreas; Eser, Tabea M; Frese, Jonathan; Ahmed, Mohamed I M; Rubio-Acero, Raquel; Guggenbuehl Noller, Jessica M; Castelletti, Noemi; Diekmannshemke, JanaUniBi
Alle
Abstract / Bemerkung
Background: Adaptive immune responses to structural proteins of the virion play a crucial role in protection against coronavirus disease 2019 (COVID-19). We therefore studied T cell responses against multiple SARS-CoV-2 structural proteins in a large cohort using a simple, fast, and high-throughput approach.; Methods: An automated interferon gamma release assay (IGRA) for the Nucleocapsid (NC)-, Membrane (M)-, Spike-C-terminus (SCT)-, and N-terminus-protein (SNT)-specific T cell responses was performed using fresh whole blood from study subjects with convalescent, confirmed COVID-19 (n = 177, more than 200 days post infection), exposed household members (n = 145), and unexposed controls (n = 85). SARS-CoV-2-specific antibodies were assessed using ElecsysAnti-SARS-CoV-2 (Ro-N-Ig) and Anti-SARS-CoV-2-ELISA (IgG) (EI-S1-IgG).; Results: 156 of 177 (88%) previously PCR confirmed cases were still positive by Ro-N-Ig more than 200 days after infection. In T cells, most frequently the M-protein was targeted by 88% seropositive, PCR confirmed cases, followed by SCT (85%), NC (82%), and SNT (73%), whereas each of these antigens was recognized by less than 14% of non-exposed control subjects. Broad targeting of these structural virion proteins was characteristic of convalescent SARS-CoV-2 infection; 68% of all seropositive individuals targeted all four tested antigens. Indeed, anti-NC antibody titer correlated loosely, but significantly with the magnitude and breadth of the SARS-CoV-2-specific T cell response. Age, sex, and body mass index were comparable between the different groups.; Conclusion: SARS-CoV-2 seropositivity correlates with broad T cell reactivity of the structural virus proteins at 200 days after infection and beyond. The SARS-CoV-2-IGRA can facilitate large scale determination of SARS-CoV-2-specific T cell responses with high accuracy against multiple targets. Copyright © 2021 Brand, Gilberg, Bruger, Gari, Wieser, Eser, Frese, Ahmed, Rubio-Acero, Guggenbuehl Noller, Castelletti, Diekmannshemke, Thiesbrummel, Huynh, Winter, Kroidl, Fuchs, Hoelscher, Roider, Kobold, Pritsch and Geldmacher.
Erscheinungsjahr
2021
Zeitschriftentitel
Frontiers in Immunology
Band
12
Art.-Nr.
688436
eISSN
1664-3224
Page URI
https://pub.uni-bielefeld.de/record/2955537

Zitieren

Brand I, Gilberg L, Bruger J, et al. Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay. Frontiers in Immunology. 2021;12: 688436.
Brand, I., Gilberg, L., Bruger, J., Gari, M., Wieser, A., Eser, T. M., Frese, J., et al. (2021). Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay. Frontiers in Immunology, 12, 688436. https://doi.org/10.3389/fimmu.2021.688436
Brand, Isabel, Gilberg, Leonard, Bruger, Jan, Gari, Merce, Wieser, Andreas, Eser, Tabea M, Frese, Jonathan, et al. 2021. “Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay”. Frontiers in Immunology 12: 688436.
Brand, I., Gilberg, L., Bruger, J., Gari, M., Wieser, A., Eser, T. M., Frese, J., Ahmed, M. I. M., Rubio-Acero, R., Guggenbuehl Noller, J. M., et al. (2021). Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay. Frontiers in Immunology 12:688436.
Brand, I., et al., 2021. Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay. Frontiers in Immunology, 12: 688436.
I. Brand, et al., “Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay”, Frontiers in Immunology, vol. 12, 2021, : 688436.
Brand, I., Gilberg, L., Bruger, J., Gari, M., Wieser, A., Eser, T.M., Frese, J., Ahmed, M.I.M., Rubio-Acero, R., Guggenbuehl Noller, J.M., Castelletti, N., Diekmannshemke, J., Thiesbrummel, S., Huynh, D., Winter, S., Kroidl, I., Fuchs, C., Hoelscher, M., Roider, J., Kobold, S., Pritsch, M., Geldmacher, C.: Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay. Frontiers in Immunology. 12, : 688436 (2021).
Brand, Isabel, Gilberg, Leonard, Bruger, Jan, Gari, Merce, Wieser, Andreas, Eser, Tabea M, Frese, Jonathan, Ahmed, Mohamed I M, Rubio-Acero, Raquel, Guggenbuehl Noller, Jessica M, Castelletti, Noemi, Diekmannshemke, Jana, Thiesbrummel, Sophie, Huynh, Duc, Winter, Simon, Kroidl, Inge, Fuchs, Christiane, Hoelscher, Michael, Roider, Julia, Kobold, Sebastian, Pritsch, Michael, and Geldmacher, Christof. “Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay”. Frontiers in Immunology 12 (2021): 688436.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Creative Commons Namensnennung 4.0 International Public License (CC-BY 4.0):
Volltext(e)
Name
Access Level
OA Open Access
Zuletzt Hochgeladen
2021-06-14T14:32:32Z
MD5 Prüfsumme
2a8fcec7c5295306160330ed5b0c6a98


Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 34093595
PubMed | Europe PMC

Suchen in

Google Scholar